Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer

Phase 3Not Yet RecruitingNCT07543536

Sun Yat-sen University132 enrolled

Overview

This study aims to evaluate whether the combination of Megestrol Acetate at the initiation of Trastuzumab Deruxtecan (T-DXd) treatment can effectively prevent and alleviate T-DXd-related fatigue, thereby improving the quality of life for advanced breast cancer patients.

Evaluate the efficacy and safety of Megestrol Acetate (MA) in improving fatigue in breast cancer patients after T-DXd treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

132

Conditions

Advanced/Metastatic Breast Cancer HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer

Interventions

Megestrol Acetate + Trastuzumab DeruxtecanDRUG

Megestrol Acetate 160mg orally, days 1-5, every 3 weeks for 2 cycles; Combined with standard Trastuzumab Deruxtecan 5.4 mg/kg IV infusion every 3 weeks

Placebo + Trastuzumab DeruxtecanDRUG

Matched placebo 160mg orally, days 1-5, every 3 weeks for 2 cycles; Combined with standard Trastuzumab Deruxtecan 5.4 mg/kg IV infusion every 3 weeks

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Female, aged 18-75 years 2. Pathologically confirmed inoperable or metastatic breast cancer with complete ER, PR, and HER2 status 3. HER2-positive (IHC 3+ or IHC 2+ with FISH positive), HER2-low (IHC 1+ or IHC 2+ with FISH negative), or HER2-ultralow (IHC 0 with ≤10% weak incomplete membrane staining) \[most recent specimen used\] 4. Investigator-assessed indication for Trastuzumab Deruxtecan (T-DXd) therapy 5. No prior treatment with Trastuzumab Deruxtecan 6. Received ≤5 lines (including 5 lines) of prior chemotherapy 7. ECOG Performance Status 0-1 8. Estimated life expectancy ≥12 weeks 9. Adequate organ function 10. Reliable contraception or negative serum/urine pregnancy test within 7 days prior to enrollment; willing to use appropriate contraception during study and for 8 weeks after last dose 11. Voluntary participation with good compliance Exclusion Criteria: 1. Severe underlying disease, comorbidities, active infection, or severe metabolic disorders 2. Clinically significant severe fatigue at baseline (FACIT-F score \<30) 3. Currently receiving other antitumor therapies 4. Pregnant or lactating patients 5. Poor compliance or unable to complete normal follow-up 6. History of allergy to megestrol acetate or other components of the formulation 7. History of thromboembolism (use with caution) 8. Other malignancies diagnosed within 5 years, except: resected non-melanoma skin cancer, adequately treated cervical carcinoma in situ, locally radically treated prostate cancer, surgically radically treated ductal carcinoma in situ, or malignancies diagnosed \>2 years ago with no current disease evidence and untreated for ≤2 years before randomization 9. Any condition judged by investigator that may affect study conduct or outcome assessment

Locations (1)

Sun yat-Sen University Cancer Center

Guangzhou, Yuexiu District, China

Outcomes

Primary Outcomes

Change in Fatigue Score (FACIT-Fatigue Scale)

Measured by Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Scale Version 4. Total score range: 0-52, with higher scores indicating less fatigue and better quality of life.

Time frame: From baseline to end of 2nd cycle (approximately 6 weeks)

Secondary Outcomes

Change in Brief Fatigue Inventory (BFI) Score

The Brief Fatigue Inventory (BFI) is a self-reported instrument designed to assess the severity and impact of cancer-related fatigue. It consists of 9 items: 3 items assess fatigue severity at its "worst," "usual," and "current" states over the past 24 hours. 1）6 items assess the degree to which fatigue interferes with daily activities (general activity, mood, walking ability, normal work, relations with other people, and enjoyment of life). 2）Scoring Criteria: Each item is rated on a 0 to 10 numerical scale, where 0 represents "no fatigue" or "does not interfere" and 10 represents "as bad as you can imagine" or "completely interferes." The total score is calculated as the average of the 9 items (range: 0-10). Mild fatigue: 1 to 3 Moderate fatigue: 4 to 6 Severe fatigue: 7 to 10 Higher scores indicate greater fatigue severity and functional impairment.

Time frame: Time Frame：Baseline (Day 1 of Cycle 1), Day 7 of Cycle 1, Cycle 2 (Day 1), Day 8 of Cycle 2, and Cycle 3 (Day 1).（each cycle is 28 days）

Objective Response Rate (ORR)

Including Complete Response (CR) and Partial Response (PR) per RECIST 1.1 criteria

Time frame: Assessed every 6 weeks up to 24 weeks

Patient Reported Outcomes (PRO)

EORTC QLQ-C30 is a 30-item questionnaire used to assess the quality of life of cancer patients. It includes: 5 Functional Scales: Physical, role, cognitive, emotional, and social functioning. 3 Symptom Scales: Fatigue, pain, and nausea/vomiting. A Global Health Status/Quality of Life (GHS/QoL) scale. 6 Single Items: Dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficultie EORTC QLQ-BR45 is a 45-item breast cancer-specific module used to assess quality of life. It consists of functional scales (e.g., body image, sexual functioning, breast satisfaction) and symptom scales (e.g., systemic therapy side effects, upset by hair loss, arm/breast symptoms, and skin/mucosal reactions to targeted therapies). Scores are linearly transformed to a range of 0 to 100. For functional scales, a higher score represents a higher level of functioning/better quality of life. For symptom scales, a higher score represents a greater symptom burden or more severe side effects

Central Contacts

Meiting Chen Doctor, PhD / Doctorate

CONTACT

02087341812 chenmt@sysucc.org.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.